FcR interactions do not play a major role in inhibition of experimental autoimmune encephalomyelitis by anti-CD154 monoclonal antibodies

Journal of Immunology

Volumn 173, Issue 2, 2004, Pages 993-999

  Nagelkerken, Lex ^a   Haspels, Inge ^a   Van Rijs, Wouter ^a   Blauw, Bep ^a   Ferrant, Janine L ^b   Hess, Donna M ^b   Garber, Ellen A ^b   Taylor, Fred R ^b   Burkly, Linda C ^b  

^a TNO   (Netherlands)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; FC RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; COMPLEMENT FIXATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GLYCOSYLATION; IMMUNOREACTIVITY; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL;

EID: 3142687550     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.2.993     Document Type: Article

References (38)

1. Grewal, I.S., and R. A. Flavell. 1908. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16:111.
2. Stuber, E., W. Strober, and M. Neurath. 1996. Blocking the CD154-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J. Exp. Med. 183:693.
3. Howland, K. C., L. I. Ausubel, C. A. London, and A. K. Abbas. 2000. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J. Immunol. 164:4465.
4. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E. Kampgen, N. Romani, and G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184:741.
5. Gerritse, K., J. D. Laman, R. J. Noelle, A. Aruffo, J. A. Ledbetter, W. J. Boersma, and E. Claassen. 1996. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA 93:2499.
6. Howard, L. M., A. J. Miga, C. L. Vanderlugt, M. C. Dal Canto, J. D. Laman, R. J. Noelle, and S. D. Miller. 1999. Mechanisms of immunotherapeutic intervention by anti-CD154 (CD154) antibody in an animal model of multiple sclerosis. J. Clin. Invest. 103:281.
7. Howard, L. M., and S. D. Miller. 2001. Autoimmune intervention by CD154 blockade prevents T cell retention and effector function in the target organ. J. Immunol. 166:1547.
8. Becher, B., M. Blain, and J. P. Antel. 2000. CD40 engagement stimulates IL-12 p70 production by human microglial cells: basis for Th1 polarization in the CNS. J. Neuroimmunol. 102:44.
9. Becher, B., B. G. Durell, A. V. Miga, W. F. Hickey, and R. J. Noelle. 2001. The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J. Exp. Med. 193:967.
10. Mendel, I., and E. M. Shevach. 2002. Differentiated Th1 autoreactive effector cells can induce experimental autoimmune encephalomyelitis in the absence of IL-12 and CD40/CD154 interactions. J. Neuroimmunol. 122:65.
11. + T cell tolerance and linked suppression. J. Immunol. 163:4805.
12. Kirk, A. D., L. C. Burkly, D. S. Batty, R. E. Baumgartner, J. D. Berning, K. Buchanan, J. H. Fechner, R. L Germond, R. L. Kampen, N. B. Patterson, et al. 1999. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates . Nat. Med. 5:686.
13. Taylor, P. A., T. M. Friedman, R. Korngold, R. J. Noelle, and B. R. Blazar. 2002. Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40: CD154 costimulatory pathway results in the generation of a potent immune regulatory cell. Blood 99:4601.
14. Graca, L., K. Honey, E. Adams, S. P. Cobbold, and H. Waldmann. 2000. Anti-CD154 therapeutic antibodies induce infectious transplantation tolerance. J. Immunol. 165:4783.
15. Sanchez-Fueyo, A., C. Domenig, T. B. Strom, and X. X. Zheng. 2002. The complement dependent cytotoxicity (CDC) immune effector mechanism contributes to anti-CD154 induced immunosuppression. Transplantation 74:898.
16. Monk, N. J., R. E. G. Hargreaves, J. E. Marsh, C. A. Farrar, S. H. Sacks, M. Millrain, E. Simpson, J. Dyson, and S. Jurcevic. 2003. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat. Med. 9:1275.
17. Nose, M., and H. Wigzell. 1983. Biological significance of carbohydrate chains on monoclonal antibodies. Proc. Natl. Acad. Sci. USA 80:6632.
18. Leatherbarrow, R. J., T. W. Rademacher, R. A. Dwek, J. M. Woof, A. Clark, D. R. Burton, N. Richardson, and A. Feinstein. 1985. Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor. Mol. Immunol. 22:407.
19. Tao, M. H., and S. L. Morrison. 1989. Studies of aglycosylated chimeric mouse-human IgG: role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143:2595.
20. Lund, J., T. Tanaka, N. Takahashi, G. Sarmay, Y. Arata, and R. Jefferis. 1990. A protein structural change in aglycosylated IgG3 correlates with loss of huFcγ R1 and huFcγ R111 binding and/or activation. Mol. Immunol. 27:1145.
21. Dorai, H., B. M. Mueller, R. A. Reisfeld, and S. D. Gillies. 1991. Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function. Hybridoma 10:211.
22. Isaacs, J. D., M. R. Clark, J. Greenwood, and H. Waldmann. 1992. Therapy with monoclonal antibodies: an in vivo model for the assessment of therapeutic potential. J. Immunol. 148:3062.
23. Friend, P. J., G. Hale, L. Chatenoud, P. Rebello, J. Bradley, S. Thiru, J. M. Phillips, and H. Waldmann. 1999. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 68:1632.
24. Boyd, P. N., A. C. Lines, and A. K. Patel. 1995. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-IH. Mol. Immunol. 32:1311.
25. Hand, P. H., B. Calvo, D. Milenic, T. Yokota, M. Finch, P. Snoy, K. Garmestani, O. Gansow, J. Schlom, and S. V. Kashmiri. 1992. Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant. Cancer Immunol. Immunother. 35:165.
26. Hobbs, S. M., L. E. Jackson, J. Hoadley. 1992. Interaction of aglycosyl immunoglobulins with the IgG Fc transport receptor from neonatal rat gut: comparison of deglycosylation by tunicamycin treatment and genetic engineering. Mol. Immunol. 29:949.
27. Nagelkerken, L., B. Blauw, and B. M. Tielemans. 1997. IL-4 abrogates the inhibitory effect of IL-10 on the development of experimental allergic encephalomyelitis in SJL mice. Int. Immunol. 9:1243.
28. + regulatory T cells contributes to skin transplant tolerance. Transplantation 76:1375.
29. Grewal, I. S., H. G. Foellmer, K. D. Grewal, J. Xu, F. Hardardottir, J. L. Baron, C. A. Janeway, and R. A. Flavell. 1996. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 273:1864.
30. Shimizu, K., U. Schonbeck, F. Mach, P. Libby, and R. N. Mitchell. 2000. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J. Immunol. 165:3506.
31. + cells. Am. J. Transplant. 1:339.
32. + T cells in vivo. Transplantation 72:1286.
33. Larsson, L. C., M. Corbascio, H. Widner, T. C. Pearson, C. P. Larsen, and H. Ekberg. 2002. Simultaneous inhibition of B7 and LFA-1 signaling prevents rejection of discordant neural xenografts in mice lacking CD154. Xenotransplantation 9:68.
34. + T cells by skin grafts via direct antigen presentation. J. Immunol. 169:1270.
35. + T cell priming for contact hypersensitivity occurs independently of CD40-CD154 interactions. J. Immunol. 166:2323.
36. Taylor, P. A., C. J. Lees, H. Waldmann, R. J. Noelle, and B. R. Blazar. 2001. Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood 98:467.
37. Howard, L. M., S. Ostrovidov, C. E. Smith, C. M. Dal Canto, and S. D. Miller. 2002. Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis. J. Clin. Invest. 109:233.
38. Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller. 1991. Sequence of Proteins of Immunological Interest, 3rd Ed., Vol. 1. National Institutes of Health, Bethesda.